Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05706311 · ClinicalTrials.gov registry record · NA

Community Pharmacy-Based Prescription Drug Monitoring Program Opioid Risk Assessment Tool

A NA study of Opioid Abuse and Prescription Opioid Abuse, sponsored by University of Utah.

Active
Registry status
NA
Development phase
80
Enrollment target
2
Study locations

NCT05706311: Active NA study of Opioid Abuse and Prescription Opioid Abuse, sponsored by University of Utah.

NCT05706311 is a NA study of Opioid Abuse and Prescription Opioid Abuse that is active but no longer recruiting, run by University of Utah. The registered enrollment target is 80 participants, below the 1,544,077-participant average among 10 other Opioid Abuse trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05706311, a NA study of Opioid Abuse and Prescription Opioid Abuse, is active but no longer recruiting, sponsored by University of Utah.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
80 participants
Enrollment target
2
Study locations

Study Summary

This goal of this observational study is to develop and test the Opioid Risk Reduction Clinical Decision Support (ORRCDS) tool. The tool will be an opioid medication risk screener and decision support platform that will be used by pharmacists upon dispensing prescription opioid medication. Once the Opioid Risk Reduction has been developed, we will examine the impact of the ORRCDS within two divisions of a large chain retail pharmacy. Pharmacies will be randomized to using the Opioid Risk Reduction Clinical Decision Support (ORRCDS) tool or standard of care opioid dispensation. We hypothesize that patients at pharmacies randomized to the ORRCDS tool will be more likely to reduce their risk status to low or moderate compared to the patients at standard of care pharmacies.

Primary Outcome

This outcome will be assessed using the System Usability Scale (SUS).

Interventions

  • OTHER Standard of Care
  • BEHAVIORAL Clinical Decision Support Tool (Moderate Risk)
  • BEHAVIORAL Clinical Decision Support Tool (High Risk)

Study Locations (2)

Ohio

  • University of Cincinnati - Cincinnati

Utah

  • University of Utah - Salt Lake City

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2025-01-21
Est. Completion 2026-05-15
Phase NA
University of Utah

818 total trials

What the registry record for NCT05706311 still lists

NCT05706311 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 1,544,077-participant average among 10 other Opioid Abuse trials with a reported enrollment target (100% lower).

The record links to 2 conditions, with Opioid Abuse appearing as the primary indexed condition, and to 3 interventions - of which Standard of Care is the first listed.

NCT05706311 reports a single indexed study location in Ohio, Utah.

Frequently Asked Questions

What is clinical trial NCT05706311 about?

NCT05706311 is a clinical study titled "Community Pharmacy-Based Prescription Drug Monitoring Program Opioid Risk Assessment Tool". This goal of this observational study is to develop and test the Opioid Risk Reduction Clinical Decision Support (ORRCDS) tool. The tool will be an opioid medication risk screener and decision support platform that will be used by pharmacists upon dispensing prescription opioid medication. Once the ...

What is the current status of trial NCT05706311?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2025-01-21. Estimated completion is 2026-05-15.

What conditions does trial NCT05706311 study?

This clinical trial studies the following conditions: Opioid Abuse, Prescription Opioid Abuse.

What interventions are being tested in trial NCT05706311?

The interventions under investigation include: Standard of Care (OTHER), Clinical Decision Support Tool (Moderate Risk) (BEHAVIORAL), Clinical Decision Support Tool (High Risk) (BEHAVIORAL).

Who is sponsoring clinical trial NCT05706311?

This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05706311 being conducted?

This trial has 2 study locations across Ohio, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid Abuse

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05706311's enrollment target sits among peer trials

80 6th of 10 higher than 5 of 10 other Opioid Abuse trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Opioid Abuse trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05706311, the US trial registry maintained by the National Library of Medicine. NCT05706311 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.